Clinical Trials match your criteria
-
Phase 2 study of Roxadustat for Treatment of Anemia
A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
-
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
-
Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
Prospective phase II Study of Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART) for Patients with Borderline or Inoperable Locally Advanced Pancreatic Cancer
-
IPI-549 Combined With Front-line Treatments in TNBC or RCC
A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma
-
Alvocidib for AML after Venetoclax Combination Tx
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax Combination Therapy
-
Safety/Effectiveness of the NanoKnife IRE for Stage 3 Pancreatic Cancer
28-001-ONC: A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
-
REGISTRY TO EVALUATE EFFECTIVENESS AND SAFETY OF THE NANOKNIFE SYSTEM FOR ABLATION OF STAGE 3 PANCREATIC ADENOCARCINOMA
REGISTRY TO EVALUATE EFFECTIVENESS AND SAFETY OF THE NANOKNIFE SYSTEM FOR THE ABLATION OF STAGE 3 PANCREATIC ADENOCARCINOMA
-
ELACESTRANT vs. SOC FOR PATIENTS WITH ER+/HER2- FOLLOWING CDK4/6 INHIBITOR THERAPY
ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL (EMERALD)
-
WARRIOR
Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
-
Therapy for Down Syndrome Kids with AML
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
